App-Quantinova.ai

Differential use of complementary and alternative medicine (CAM) in cancer patients at a single institution.

Prabhsimranjot Singh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

The relationship between carnitine pharmacokinetics and fatigue in cancer patients treated with cisplatin-containing chemotherapy.

Tatsuhiko Kashii - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carnitine

Integrating palliative care in pediatric oncology: An evolving paradigm for comprehensive cancer care.

Deena R. Levine - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Group acupuncture appointments for cancer-related symptoms: A retrospective review of the first year of experience at the Levine Cancer Institute.

Wendy G. Brick - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Intravenous ferric carboxymaltose treatment in cancer patients.

Alma Aslan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Ferric carboxymaltose

Applications of wearable activity monitors (WAM) in cancer clinical trials (CT): A review of the literature.

Gillian K. Gresham - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of Spirulina in the supportive treatment associated to palliative chemotherapy in patients with advanced oncologic disease.

Silvia Regina Graziani - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Study of patient risk factors for febrile neutropenia in non-Hodgkin lymphoma receiving R-CHOP regimen: STOP FN single institution analysis in Japan.

Masahiro Yokoyama - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Defense mechanisms and coping style at very next diagnostic period in advanced and metastatic cancer. - Publication Only: Patient and Survivor Care

Anda Natalia Ciuhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Oral mucositis in cancer treatment: Cross-national perspective of oncologists in Asia and Saudi Arabia.

Hanlim Moon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Real-world efficacy of epoetin zeta for chemotherapy-induced anemia in patients with solid tumors: A sub-analysis of the SYNERGY study.

Florian Scotte - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Epo-zeta

Analysis of the background of neuropathic pain due to cancer and the factors that affect its control.

Kazuki Tahara - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Implementation of a protocol of nutritional support in cancer patients.

Adrian Pablo Hunis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient reported outcomes of red blood cell transfusions in an ambulatory oncology population.

Lawrence David Wagman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy of ginger for chemotherapy-induced nausea and vomiting (CINV) prophylaxis in breast cancer patients receiving adriamycin cyclophosphamide (AC) regimen: Randomized double-blind placebo-control crossover study.

Lucksamon Thamlikitkul - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

Incidence, characteristics and treatment of fatigue in oncological cancer patients (PTS) in Italy: A cross-sectional study.

Fausto Roila - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adverse events associated with checkpoint and signal transduction inhibitors in unselected survivors with metastatic melanoma.

Taryn A Gitter - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The impact of a simplified documentation method for the Edmonton Classification System for Cancer Pain (ECS-CP) on clinician utilization.

Kimberson Tanco - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

A phase II randomized study to evaluate a new psychosocial intervention (PI) plus early palliative care (PC) in the reduction of depression of advanced cancer patients (ACP): The PREPArE trial.

Carlos Eduardo Paiva - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Outpatient oncology massage self-reported outcomes in cancer patients and their caregivers.

Gabriel Lopez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Filters

41730 Abstracts